Apricoxib, A COX-2 inhibitor for the potential treatment of pain and cancer

IDrugs

Volumn 12, Issue 11, 2009, Pages 711-722

  Praveen Rao, P N ^a   Grover, Rajesh K ^b  

^a UNIVERSITY OF WATERLOO   (Canada)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; APRICOXIB; C5 706; CAPECITABINE; CELECOXIB; CISPLATIN; CYCLOOXYGENASE 2 INHIBITOR; CYTOCHROME P450; DOCETAXEL; ERLOTINIB; FLUOROURACIL; GEMCITABINE; LAPATINIB; NAPROXEN; PEMETREXED; PLACEBO; ROFECOXIB; TRASTUZUMAB; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; BLOOD PRESSURE; BREAST CANCER; CHRONIC ARTHRITIS; CLINICAL TRIAL; COLORECTAL CANCER; CONSTIPATION; CONTROLLED CLINICAL TRIAL; DENTAL SURGERY; DIARRHEA; DIGESTIVE SYSTEM INJURY; DIZZINESS; DRUG ABSORPTION; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG ERUPTION; DRUG EXCRETION; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERABILITY; DYSPNEA; FAMILIAL COLON POLYPOSIS; FEVER; HALF LIFE TIME; HEADACHE; HUMAN; IC 50; IN VITRO STUDY; IN VIVO STUDY; LETHAL DOSE; LIFESPAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NEOPLASM; NONHUMAN; OSTEITIS; OVERALL SURVIVAL; PAIN; PANCREAS CANCER; PARESTHESIA; PHARYNGITIS; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; STOMACH ULCER; TOOTH PAIN; TREATMENT RESPONSE; UPPER ABDOMINAL PAIN; UREA NITROGEN BLOOD LEVEL; VOMITING;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE II AS TOPIC; CYCLOOXYGENASE 2 INHIBITORS; HUMANS; INFLAMMATION; NEOPLASMS; PAIN; PYRROLES; SULFONAMIDES;

EID: 70350257912     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. 445612 R-109339, a novel COX-2 inhibitor, has potent antitumor and anticachectic activities in colon 26 tumor-bearing mice. Kurakata S, Hanai M, Kanai S, Shibata M, Yada A, Tanzawa F, Yamada T, Ushiyama S PROC AM ASSOC CANCER RES 2002 43 Abs 365
2. 446043 R-109339, a novel COX-2 inhibitor, has potent chemopreventive effects on colorectal tumorigenesis. Hanai M, Kanai S, Shibata M, Yada A, Kamai Y, Tani Y, Ushiyama S, Kurakata S PROC AM ASSOC CANCER RES 2002 43 Abs 619
3. 484666 Distribution of CS-706 (R-109339), a novel COX-2 inhibitor, in tumor bearing mice: Comparative study with celecoxib. Inoue S i, Ishigami M, Fujimori I, Takasaki W, Tokui T, Hanai M, Kanai S, Shibata M, Kurakata S I PROC AM ASSOC CANCER RES 2003 44 Abs 1730
4. 490534 The new coxib drug R-109339 is a very effective chemopreventive agent for decreasing adenoma multiplicity. Jacoby RF, Cole CE, Lubet RA GASTROENTEROLOGY 2003 124 Suppl 1 Abs S1660
5. 497643 Prevention and regression by non-steroidal anti-inflammatory drugs and other agents of azoxymethane-induced aberrant crypt foci in rat colon. Kramer PM, Lubet RA, Steele VE, Clausing AK, Pereira MA PROC AM ASSOC CANCER RES 2003 44 1st Ed Abs 4927
6. 497763 Studies on the antitumor activities of CS-706 (R-109339), a novel COX-2 inhibitor: Influence of the administration schedule and combination effects with cisplatin. Hanai M, Fujiwara K, Kanai S, Shibata S, Yada A, Tanzawa F, Ushiyama S, Kimura T, Kurakata S PROC AM ASSOC CANCER RES 2003 44 1st Ed Abs 4621
7. 497765 CS-706 (R-109339), a novel COX-2 inhibitor, inhibits tumor-induced hypercalcemia and bone resorption in colon 26 tumor-bearing mice. Shibata M, Fujiwara K, Hanai M, Kanai S, Yada A, Kiyokawa A, Kato S, Miyamoto M, Kurakata S PROC AM ASSOC CANCER RES 2003 44 1st Ed Abs 4622
8. 554166 Research and development pipeline. Sankyo Co Ltd COMPANY WORLD WIDE WEB SITE 2004 July 30
9. 561739 Merck announces voluntary worldwide withdrawal of Vioxx. Merck & Co Inc PRESS RELEASE 2004 September 30
10. 616169 Celebrex - Celebrex capsules. Pfizer Inc DRUG PACKAGE INSERT 2005 July 29
11. 693899 Celecoxib for the prevention of sporadic colorectal adenomas. Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim KM, Tang J, Rosenstein RB, Wittes J, Corle D, Hess TM, et al N ENGL J MED 2006 355 9 873-884
12. 772259 A randomized, double-blind, one-week study comparing effects of a novel COX-2 inhibitor and naproxen on the gastric mucosa. Moberly JB, Harris SI, Riff DS, Dale JC, Breese T, McLaughlin P, Lawson J, Wan YP, Xu JB, Truitt KE DIG DIS SCI 2007 52 2 442-450
13. 774297 Tragara Pharmaceuticals, Inc. announces corporate launch and series A financing. Tragara Pharmaceuticals Inc PRESS RELEASE 2007 March 14
14. 781446 Predictive population pharmacokinetic/pharmacodynamic model for a novel COX-2 inhibitor. Rohatagi S, Kastrissios H, Gao Y, Zhang N, Xu J, Moberly J, Wada R, Yoshihara K, Takahashi M, Truitt K, Salazar D J CLIN PHARMACOL 2007 47 3 358-370
15. 800658 A randomized, double-blind, celecoxib- and placebocontrolled study of the effectiveness of CS-706 in acute postoperative dental pain. Moberly JB, Xu J, Desjardins PJ, Daniels SE, Bandy DR, Lawson JE, Link AJ, Truitt KE CLIN THER 2007 29 3 399-412
16. 824012 Therapeutic effect of CS-706, a specific cyclooxygenase-2 inhibitor, on gallbladder carcinoma in BK5.ErbB-2 mice. Kiguchi K, Ruffino L, Kawamoto T, Franco E, Kurakata SI, Fujiwara K, Hanai M, Rumi M, DiGiovanni J MOL CANCER THER 2007 6 6 1709-1717
17. 883335 CS-706, a novel cyclooxygenase-2 selective inhibitor, prolonged the survival of tumor-bearing mice when treated alone or in combination with anti-tumor chemotherapeutic agents. Senzaki M, Ishida S, Yada A, Hanai M, Fujiwara K, Inoue SI, Kimura T, Kurakata S INT J CANCER 2008 122 6 1384-1390
18. 894753 Activity of TG01, a selective COX-2 inhibitor, alone and in combination with standard agents in human breast carcinoma xenografts. Zaknoen SL, Lawhon TL, Meade MA, Leopold RR, Wong AK, Meshaw KR, Johnson RK AM ASSOC CANCER RES ANN MEET 2008 99 Abs 5662
19. 894756 Activity of TG01, a selective COX-2 inhibitor, alone and in combination with docetaxel in human non-small cell lung carcinoma xenografts. Lawhon TL, Zaknoen SL, Wong AJ et al AM ASSOC CANCER RES ANN MEET 2008 99 Abs 5663
20. 895486 NCT00652340: Randomized, double-blind, placebo controlled study to evaluate efficacy and safety of apricoxib with erlotinib in patients with non-small cell lung cancer (TP2001-201). Tragara Pharmaceuticals Inc CLINICALTRIALS.GOV 2008 April 18
21. 945280 Biologic therapies in rheumatology: Lessons learned, future directions. Strand V, Kimberly R, Isaacs JD NAT REV DRUG DISCOV 2007 6 1 75-92
22. 950107 Lapatinib: A dual inhibitor of human epidermal growth factor receptor tyrosine kinases. Medina PJ, Goodin S CLIN THER 2008 30 8 1426-1447
23. 993506 Tragara Pharmaceuticals company website and pipeline. Tragara Pharmaceuticals Inc COMPANY WORLD WIDE WEB SITE 2009 March 23
24. 997876 Biomarker based phase I study of apricoxib, a potent COX-2 inhibitor in combination with erlotinib in non-small cell lung cancer (NSCLC) patients. Reckamp KL, Patel R, Gitlitz B, Chen L, Jezior D, Zaknoen S AM ASSOC CANCER RES ANN MEET 2009 100 Abs 5621
25. 1031375 The differences among CS-706, a novel selective cyclo-oxygenase-2 inhibitor, celecoxib and rofecoxib in their distribution to the arteries of rats; Safety assessment from the viewpoint of cardiovascular risks. Oitate M, Hilota T, Koyama K, Inoue S, Kawai K, Ikeda T ANN RHEUM DIS 2006 65 343-344
26. 1031376 Preclinical pharmacology of CS-706, a novel cyclooxygenase-2 selective inhibitor, with optimal COX-2 selectivity and greater analgesic efficacy. Ushiyama S, Nakajima TY, Murakami Y, Kumakura S ANN RHEUM DIS 2006 65 347-347
27. 1031377 Development of a predictive pharmacokinetic model for a novel cyclooxygenase-2 inhibitor. Kastrissios H, Rohatagi S, Moberly J, Truitt K, Gao Y, Wada R, Takahashi M, Kawabata K, Salazar D J CLIN PHARMACOL 2006 46 5 537-548
28. 1031379 Covalent binding of radioactivity from [C-14]rofecoxib, but not [C-14]celecoxib or [C-14]CS-706, to the arterial elastin of rats. Oitate M, Hirota T, Koyama K, Inoue S, Kawai K, Ikeda T DRUG METAB DISPOS 2006 34 8 1417-1422 Preclinical study disclosing the lack of accumulation and retention of radioactivity in the thoracic aorta of rats after the oral administration of [14C]apricoxib, suggesting decreased cardiovascular adverse events for the drug compared with rofecoxib.
29. 1031380 Covalent binding of rofecoxib, but not other cyclooxygenase-2 inhibitors, to allysine aldehyde in elastin of human aorta. Oitate M, Hirota T, Murai T, Miura SI, Ikeda T DRUG METAB DISPOS 2007 35 1846-1852
30. 1031381 Preclinical pharmacology profile of CS-706, a novel cyclooxygenase-2 selective inhibitor, with potent antinociceptive and anti-inflammatory effects. Ushiyama S, Yamada T, Murakami Y, Kumakura SI, Inoue SI, Suzuki K, Nakao A, Kawara A, Kimura T EUR J PHARMACOL 2008 578 1 76-86
31. 1031382 Pain relief model for a COX-2 inhibitor in patients with postoperative dental pain. Rohatagi S, Kastrissios H, Sasahara K, Truitt K, Moberly JB, Wada R, Salazar DE BR J CLIN PHARMACOL 2008 66 1 60-70
32. 1031496 Mechanisms of disease: Cytokine pathways and joint inflammation in rheumatoid arthritis. Choy EHS, Panayi GS N ENGL J MED 2001 344 12 907-916
33. 1031497 Osteoarthritis, angiogenesis and inflammation. Bonnet CS, Walsh DA RHEUMATOLOGY 2005 44 1 7-16
34. 1031499 Cytokines and their relationship to the symptoms and outcome of cancer. Seruga B, Zhang HB, Bernstein LJ, Tannock IF NAT REV CANCER 2008 8 11 887-899
35. 1031502 Why neurodegenerative diseases are progressive: Uncontrolled inflammation drives disease progression. Gao HM, Hong JS TRENDS IMMUNOL 2008 29 8 357-365
36. 1031504 Inflammation and neurodegenerative diseases. Griffin WST AM J CLIN NUTR 2006 83 2 470S-474S
37. 1031507 Inflammation in central nervous system injury. Allan SM, Rothwell NJ PHILOS TRANS R SOC LOND B-BIOL SCI 2003 358 1438 1669-1677
38. 1031509 The fight against rheumatism: From willow bark to COX-1 sparing drugs. Vane JR J PHYSIOL PHARMACOL 2000 51 4 573-586
39. 1031510 COX isoforms in the cardiovascular system: Understanding the activities of non-steroidal anti-inflammatory drugs. Mitchell JA, Warner TD NAT REV DRUG DISCOV 2006 5 1 75-85
40. 1031511 Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events - Meta-analysis of randomized trials. Zhang JJ, Ding EL, Song YQ JAMA-J AM MED ASSOC 2006 296 13 1619-1632
41. 1031512 Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): Cyclooxygenase (COX) inhibition and beyond. Rao PNP, Knaus EE J PHARMACY PHARMACEUTIC SCI 2008 11 2 81-110
42. 1031513 NSAIDs and cancer prevention: Targets downstream of COX-2. Cha YI, DuBois RN ANNU REV MED 2007 58 239-252
43. 1031514 Rheumatoid arthritis market. Mount C, Featherstone J NAT REV DRUG DISCOV 2005 4 1 11-12
44. 1031533 Systemic treatment of colorectal cancer. Wolpin BM, Mayer RJ GASTROENTEROLOGY 2008 134 5 1296-1310
45. 1031537 Celecoxib analogs that lack COX-2 inhibitory function: Preclinical development of novel anticancer drugs. Schonthal AH, Chen TC, Hofman FM, Louie SG, Petasis NA EXPERT OPIN INVEST DRUGS 2008 17 2 197-208
46. 1031538 A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer. Reckamp KL, Krysan K, Morrow JD, Milne GL, Newman RA, Tucker C, Elashoff RM, Dubinett SM, Figlin RACLIN CANCER RES 2006 12 11 3381-3388
47. 1031539 Modulation of breast cancer risk by nonsteroidal anti-inflammatory drugs. Howe LR, Lippman SM J NATL CANCER INST 2008 100 20 1420-1423
48. 1031541 Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with trastuzumab-insensitive human epidermal growth factor receptor 2-positive metastatic breast cancer. Portera CC, Walshe JM, Rosing DR, Denduluri N, Berman AW, Vatas U, Velarde M, Chow CK, Steinberg SM, Nguyen D, Yang SX, Swain SM CLIN CANCER RES 2008 14 9 2710-2716
49. 1036825 FDA announces series of changes to the class of marketed non-steroidal anti-inflammatory drugs (NSAIDs). The Food and Drug Administration PRESS RELEASE 2005 April 07
50. 1040367 Inflammatory resolution: New opportunities for drug discovery. Gilroy DW, Lawrence T, Perretti M, Rossi AG NAT REV DRUG DISCOV 2004 3 5 401-416
51. 1040368 Cyclooxygenase-2 inhibitors in gynecologic practice. Connolly TP CLIN MED RES 2003 1 2 105-110
52. 1040372 New treatment for advanced cancer: An approach to prioritization. Ferguson JSJ, Summerheyes M, Masters S, Schey S, Smith IE BR J CANCER 2000 83 10 1268-1273
53. 1040376 Newer cytotoxic agents: Attacking cancer broadly. Teicher BA CLIN CANCER RES 2008 14 6 1610-1617
54. 1040377 Endocrine therapy and other targeted therapies for metastatic breast cancer. Hussain SA, Palmer DH, Moon S,Rea DW EXPERT REV ANTICANCER THER 2004 4 6 1179-1195
55. 1040378 Stemming resistance to HER-2 targeted therapy. Bedard PL, Cardoso F, Piccart-Gebhart MJ J MAMMARY GLAND BIOL NEOPLASIA 2009 14 1 55-66
56. 1040379 Combined therapies for cancer: A review of EGFR-targeted monotherapy and combination treatment with other drugs. Zahorowska B, Crowe PJ, Yang JL J CANCER RES CLIN ONCOL 2009 135 9 1137-1148
57. 1040380 Antiangiogenic versus cytotoxic therapeutic approaches in a mouse model of pancreatic cancer: An experimental study with a multitarget tyrosine kinase inhibitor (sunitinib), gemcitabine and radiotherapy. Casneuf VF, Demetter P, Boterberg T, Delrue L, Peeters M, Van Damme M ONCOL REP 2009 22 1 105-113
58. 1040382 Side effects of chemotherapy and combined chemohormonal therapy in women with early-stage breast cancer. Partridge AH, Burstein HJ, Winer EP J NATL CANCER INST 2001 30 135-142
59. 1040383 Molecular mechanisms of chemotherapy-induced hair loss. Botchkarev VA J INVEST DERMATOL SYMP PROC 2003 8 1 72-75
60. 1040387 Mechanisms of drug resistance in cancer chemotherapy. Luqmani YA MED PRINCIPLES PRACT 2005 14 Suppl 1 35-48
61. 1040394 Physiological regulation of cyclooxygenase-2 in the kidney. Harris RC, Breyer MD AM J PHYSIOL - RENAL PHYSIOL 2001 281 1 F1-F11
62. 1040395 Parenteral ketorolac and risk of gastrointestinal and operative site bleeding. A postmarketing surveillance study. Strom BL, Berlin JA, Kinman JL, Spitz PW, Hennessy S, Feldman H, Kimmel S, Carson JL JAMA-J AM MED ASSOC 1996 275 5 376-382
63. 1040396 Prostaglandin E2 activates mitogen-activated protein kinase/ERK pathway signaling and cell proliferation in non-small cell lung cancer cells in an epidermal growth factor receptor-independent manner. Krysan K, Reckamp KL, Dalwadi H, Sharma S, Rozengurt E, Dohadwala M, Dubinett SM CANCER RES 2005 65 14 6275-6281
64. 1040454 Cyclooxygenase-2 (COX-2) and the inflammogenesis of cancer. Harris RE INFLAMM PATHOGENESIS CHRONIC DIS (ED: HARRIS RE) 2007 Springer 93-126
65. 1040496 Approach to the patient with cancer. Fetting JH PRINCIPLES PRACT MED (EDS: STOBO JD, TRAILL TA, HELLMANN DB, LADENSON PW, PETTY BG) 1996 McGraw-Hill Medical 23 771-774